Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin

Anemia-Related Outcomes in Patients with CKD Treated with Dapagliflozin This study aims to identify factors that predict anemia improvement in chronic kidney disease (CKD) patients using Dapagliflozin, an SGLT2 inhibitor. Key questions: * What factors influence how well Dapagliflozin improves anemia in CKD patients? * Are there specific characteristics that predict better responses to Dapagliflozin treatment? The investigators will review medical records of CKD patients who started taking Dapagliflozin. The investigators will compare those with low hemoglobin levels (anemia) to those without anemia. The investigators will analyze: Changes in hemoglobin levels Other factors related to anemia (e.g., iron levels, TIBC, ferritin) Patient characteristics (e.g., age, sex, CKD stage) This study will help us understand which CKD patients are most likely to benefit from Dapagliflozin for anemia.

NCT Number	NCT06813222
Lead Sponsor	Damanhour University
Conditions	Anemia, CKD
Enrollment	100 participants
Start Date	2021-04-01
Primary Completion	2025-03-01 (estimated)
Study Completion	2025-03-01 (estimated)
Updated on ClinicalTrials.gov	2025-02-06